Aurdan Capital Management LLC Makes New $6.59 Million Investment in Amgen Inc. (NASDAQ:AMGN)

Aurdan Capital Management LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 25,275 shares of the medical research company's stock, valued at approximately $6,588,000. Amgen makes up about 2.5% of Aurdan Capital Management LLC's investment portfolio, making the stock its 12th biggest holding.

Several other large investors also recently bought and sold shares of the business. Grassi Investment Management grew its position in shares of Amgen by 4.5% during the 4th quarter. Grassi Investment Management now owns 4,600 shares of the medical research company's stock worth $1,199,000 after buying an additional 200 shares in the last quarter. Tallon Kerry Patrick acquired a new stake in shares of Amgen in the fourth quarter worth approximately $270,000. Secure Asset Management LLC raised its stake in Amgen by 138.4% in the 4th quarter. Secure Asset Management LLC now owns 2,248 shares of the medical research company's stock valued at $586,000 after purchasing an additional 1,305 shares during the last quarter. Veracity Capital LLC lifted its holdings in Amgen by 24.6% in the 4th quarter. Veracity Capital LLC now owns 1,186 shares of the medical research company's stock valued at $309,000 after purchasing an additional 234 shares in the last quarter. Finally, Brighton Jones LLC grew its holdings in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after buying an additional 5,226 shares in the last quarter. Institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on AMGN. Citigroup reaffirmed a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Guggenheim started coverage on Amgen in a research note on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price target on the stock. Piper Sandler reduced their price objective on Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a research note on Friday, May 16th. Mizuho lifted their price target on Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a report on Wednesday, May 7th. Finally, Bank of America boosted their price target on Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a research note on Wednesday, March 5th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $309.22.

Amgen Stock Up 1.3%

Shares of Amgen stock traded up $3.62 on Friday, reaching $287.16. 1,427,946 shares of the company were exchanged, compared to its average volume of 2,797,462. The company has a market capitalization of $154.40 billion, a price-to-earnings ratio of 38.03, a PEG ratio of 2.63 and a beta of 0.51. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a 50-day moving average of $283.86 and a 200 day moving average of $285.50.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. The business had revenue of $8.15 billion for the quarter, compared to analysts' expectations of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm's revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.96 EPS. On average, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.32%. Amgen's dividend payout ratio (DPR) is currently 86.86%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.